Astellas FY17 Results and FY18e Guidance – No Major Surprise
Astellas Pharma Inc (4503 JP) FY17 results Xtandi (up 17% to ¥295b) and mirabegron (up 28% to ¥126b) ramp-up compensate for lackluster domestic...
120 Views
Japan Pharma - FY17e Earnings Preview (I)
Astellas Pharma Inc (4503 JP) - April 26, 2018FY18e potential guidance Moderate Xtandi and Tarceva growth and Vesicare US patent expiry led y-o-y...
98 Views
Global Equity Strategy: Opportunities in Japan, HK, & EM
In our April International Strategy, we explore the recent consolidation across global equity markets and examine the following opportunities...
194 Views
Japan Pharmaceutical - Sector Overview
Core coverage – relative valuations Takeda Pharmaceutical Co Ltd (4502 JP) (NB: Pre-Shire announcement | Pro-Forma analysis to be published...
156 Views
Trading the BOJ-Nikkei 225 Baskets
One week ago in The BOJ's Ongoing ETF Impact - Is a Nikkei 225 Reshuffle in the Cards? I discussed the BOJ's past and current ETF purchasing...
469 Views